ORMP insider transaction filings
ORAMED PHARMACEUTICALS INC. — 31 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-02. Screen ORMP transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-02 | 4 | Hexter Joshua — COO & CBO | Sale (S): 137,000 @ $4.46 · Option exercise (M): 50,000 @ $3.69 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Gabay Avraham — Chief Financial Officer | Sale (S): 73,360 @ $4.51 | EDGAR |
| 2026-03-31 | 4 | KIDRON NADAV — President and CEO, Director | Tax withholding (F): 44,818 @ $3.31 | EDGAR |
| 2026-03-31 | 4 | Kidron Miriam — Chief Scientific Officer, Director | Tax withholding (F): 435,084 @ $3.31 | EDGAR |
| 2026-03-18 | 4 | Kidron Miriam — Chief Scientific Officer, Director | Grant/award (A): 119,558 @ $0 | EDGAR |
| 2026-03-18 | 4 | KIDRON NADAV — President and CEO, Director | Grant/award (A): 167,005 @ $0 | EDGAR |
| 2026-03-18 | 4 | Hexter Joshua — COO & CBO | Grant/award (A): 95,889 @ $0 | EDGAR |
| 2026-03-18 | 4 | Gabay Avraham — Chief Financial Officer | Grant/award (A): 95,889 @ $0 | EDGAR |
| 2026-03-16 | 4 | KIDRON NADAV — President and CEO, Director | Gift (G): 100,000 @ $0 | EDGAR |
| 2026-01-29 | 4 | KIDRON NADAV — President and CEO, Director | Option exercise (M): 109,000 @ $0 · Option exercise (M): 109,000 (derivative) @ $0 | EDGAR |
| 2026-01-29 | 4 | Kidron Miriam — Chief Scientific Officer, Director | Option exercise (M): 19,000 @ $0 · Option exercise (M): 19,000 (derivative) @ $0 | EDGAR |
| 2026-01-29 | 4 | Hexter Joshua — COO & CBO | Option exercise (M): 19,000 @ $0 · Option exercise (M): 19,000 (derivative) @ $0 | EDGAR |
| 2026-01-29 | 4 | Gabay Avraham — Chief Financial Officer | Option exercise (M): 19,000 @ $0 · Option exercise (M): 19,000 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Kidron Miriam — Chief Scientific Officer, Director | Gift (G): 86,166 @ $0 | EDGAR |
| 2026-01-05 | 4 | Reznick Yehuda — Director | Grant/award (A): 30,000 · Grant/award (A): 6,250 | EDGAR |
| 2026-01-05 | 4 | KIDRON NADAV — President and CEO, Director | Grant/award (A): 232,640 @ $0 · Grant/award (A): 327,000 @ $0 · Grant/award (A): 109,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Kidron Miriam — Chief Scientific Officer, Director | Grant/award (A): 121,331 @ $0 · Grant/award (A): 115,000 @ $0 · Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Hexter Joshua — COO & CBO | Grant/award (A): 97,328 @ $0 · Grant/award (A): 115,000 @ $0 · Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Shapiro Benjamin — Director | Grant/award (A): 30,000 · Grant/award (A): 3,500 | EDGAR |
| 2026-01-05 | 4 | Mayer Arie — Director | Grant/award (A): 30,000 · Grant/award (A): 4,900 | EDGAR |
| 2026-01-02 | 4 | Aghion Daniel — Director | Grant/award (A): 30,000 · Grant/award (A): 6,250 | EDGAR |
| 2026-01-02 | 4 | Gabay Avraham — Chief Financial Officer | Grant/award (A): 81,216 @ $0 · Grant/award (A): 115,000 @ $0 · Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Mayer Arie — Director | Grant/award (A): 30,000 · Grant/award (A): 6,975 | EDGAR |
| 2025-06-09 | 4 | Aghion Daniel — Director | Grant/award (A): 30,000 · Grant/award (A): 8,371 | EDGAR |
| 2025-06-09 | 4 | Reznick Yehuda — Director | Grant/award (A): 30,000 · Grant/award (A): 8,370 | EDGAR |
| 2025-06-09 | 4 | Sank Leonard — Director | Grant/award (A): 30,000 · Grant/award (A): 6,510 | EDGAR |
| 2025-06-09 | 4 | Shapiro Benjamin — Director | Grant/award (A): 30,000 · Grant/award (A): 4,650 | EDGAR |
| 2025-02-11 | 4 | Kidron Miriam — Chief Scientific Officer, Director | Grant/award (A): 74,000 @ $0 · Grant/award (A): 52,000 @ $0 · Grant/award (A): 66,667 @ $0 | EDGAR |
| 2025-02-11 | 4 | Hexter Joshua — COO & CBO | Grant/award (A): 45,000 @ $0 · Grant/award (A): 48,500 @ $0 · Grant/award (A): 33,334 @ $0 | EDGAR |
| 2025-02-11 | 4 | KIDRON NADAV — President and CEO, Director | Grant/award (A): 141,000 @ $0 · Grant/award (A): 186,000 @ $0 · Grant/award (A): 100,000 @ $0 | EDGAR |
| 2025-02-11 | 4 | Gabay Avraham — Chief Financial Officer | Grant/award (A): 34,000 @ $0 · Grant/award (A): 42,000 @ $0 | EDGAR |
Recent 8-K events — ORAMED PHARMACEUTICALS INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-06-30 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-31 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets | EDGAR |
| 2026-02-20 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-07 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-31 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-12-31 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-11-17 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.03 — Material Modification to Rights of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ORMP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →